Editas Medicine Q3 net loss narrows, beats expectations

Reuters

Nov 10

<a href="https://laohu8.com/S/EDIT">Editas Medicine</a> Q3 net loss narrows, beats expectations

Overview

Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations
Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement
Company extends cash runway into Q3 2027, supporting EDIT-401 progression

Outlook

Editas plans to submit IND/CTA for EDIT-401 by mid-2026
Company aims for initial human proof-of-concept data for EDIT-401 by end-2026
Editas extends cash runway into Q3 2027, supporting EDIT-401 progression

Result Drivers

BMS MILESTONE - Collaboration revenue increase attributed to milestone achievement under BMS agreement

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration and other research and development revenue		$7.50 mln
Q3 EPS		-$0.28
Q3 Net Income	Beat	-$25.12 mln	-$28.10 mln (11 Analysts)
Q3 Basic EPS		-$0.28
Q3 Operating Expenses		$32.09 mln
Q3 Operating Income		-$24.55 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 38.2% above its November 7 closing price of $2.47

Press Release: ID:nGNX278KVY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2582873084"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582873084\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582873084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582873084","market":"us","top_or_hot":-1,"title":"Editas Medicine Q3 net loss narrows, beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> Q3 net loss narrows, beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations</p></li><li><p>Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement</p></li><li><p>Company extends cash runway into Q3 2027, supporting EDIT-401 progression</p></li></ul><p><span>Outlook</span></p><ul><li><p>Editas plans to submit IND/CTA for EDIT-401 by mid-2026</p></li><li><p>Company aims for initial human proof-of-concept data for EDIT-401 by end-2026</p></li><li><p>Editas extends cash runway into Q3 2027, supporting EDIT-401 progression</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BMS MILESTONE - Collaboration revenue increase attributed to milestone achievement under BMS agreement</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration and other research and development revenue</p></td><td></td><td><p>$7.50 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$25.12 mln</p></td><td><p>-$28.10 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$32.09 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$24.55 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 6 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 38.2% above its November 7 closing price of $2.47</p></li></ul><p>Press Release: <span>ID:nGNX278KVY</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Editas Medicine Q3 net loss narrows, beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEditas Medicine Q3 net loss narrows, beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EDIT\">Editas Medicine</a> Q3 net loss narrows, beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Editas Q3 net loss decreases to $25.1 mln, beating analyst expectations</p></li><li><p>Collaboration revenue rises to $7.5 mln, driven by BMS milestone achievement</p></li><li><p>Company extends cash runway into Q3 2027, supporting EDIT-401 progression</p></li></ul><p><span>Outlook</span></p><ul><li><p>Editas plans to submit IND/CTA for EDIT-401 by mid-2026</p></li><li><p>Company aims for initial human proof-of-concept data for EDIT-401 by end-2026</p></li><li><p>Editas extends cash runway into Q3 2027, supporting EDIT-401 progression</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>BMS MILESTONE - Collaboration revenue increase attributed to milestone achievement under BMS agreement</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration and other research and development revenue</p></td><td></td><td><p>$7.50 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$25.12 mln</p></td><td><p>-$28.10 mln (11 Analysts)</p></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$32.09 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$24.55 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 6 \"hold\" and 2 \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 38.2% above its November 7 closing price of $2.47</p></li></ul><p>Press Release: <span>ID:nGNX278KVY</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EDIT","symbol_name":"Editas Medicine, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D7:1","article_id":"2582873084","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582873084","pubTimestamp":1762776515,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Editas Medicine Q3 net loss narrows, beats expectationsOverviewEditas Q3 net loss decreases to $25.1 mln, beating analyst expectationsCollaboration revenue rises to $7.5 mln, driven by BMS milestone a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EDIT":"Editas Medicine, Inc.","BK4556":"基因编辑","BK4139":"生物科技"},"translate_title":"Editas Medicine第三季度净亏损收窄，超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EDIT":0.9},"content_text":"Editas Medicine Q3 net loss narrows, beats expectationsOverviewEditas Q3 net loss decreases to $25.1 mln, beating analyst expectationsCollaboration revenue rises to $7.5 mln, driven by BMS milestone achievementCompany extends cash runway into Q3 2027, supporting EDIT-401 progressionOutlookEditas plans to submit IND/CTA for EDIT-401 by mid-2026Company aims for initial human proof-of-concept data for EDIT-401 by end-2026Editas extends cash runway into Q3 2027, supporting EDIT-401 progressionResult DriversBMS MILESTONE - Collaboration revenue increase attributed to milestone achievement under BMS agreementKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration and other research and development revenue$7.50 mlnQ3 EPS-$0.28Q3 Net IncomeBeat-$25.12 mln-$28.10 mln (11 Analysts)Q3 Basic EPS-$0.28Q3 Operating Expenses$32.09 mlnQ3 Operating Income-$24.55 mlnAnalyst CoverageThe current average analyst rating on the shares is \"hold\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 6 \"hold\" and 2 \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 38.2% above its November 7 closing price of $2.47Press Release: ID:nGNX278KVYFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}